| Dr Thomas F Cahill, MD | |
|
300 Hanover St, Fall River, MA 02720-5444 | |
| (508) 679-7709 | |
| Not Available |
| Full Name | Dr Thomas F Cahill |
|---|---|
| Gender | Male |
| Speciality | Otolaryngology |
| Experience | 55 Years |
| Location | 300 Hanover St, Fall River, Massachusetts |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1760421291 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Y00000X | Otolaryngology | 40774 (Massachusetts) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Saint Anne's Hospital | Fall river, MA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Prima Care Pc | 2567356017 | 186 |
News Archive
A team of scientists, led by researchers at the University of California, San Diego School of Medicine, has shown for the first time how cancer cells control the ON/OFF switch of a program used by developing embryos to effectively metastasize in vivo, breaking free and spreading to other parts of the body, where they can proliferate and grow into secondary tumors.
A new research paper published by scientists at the University of Bristol who sequenced the genome of the SARS-CoV-2 virus, which is causing the worldwide COVID-19 illness, reveals some significant findings that could help researchers working on rolling out vaccines to stop the relentless march of the virus. The study was published online on the preprint site bioRxiv in April 2020.
OncoMed Pharmaceuticals, Inc., a company developing novel therapeutics that target cancer stem cells, announced today that it has been awarded $1.2 million to support five distinct therapeutic programs under the U.S. Government's Qualifying Therapeutic Discovery Project program.
Genzyme, a Sanofi company, announced today the formation of a research collaboration with Cleveland Clinic focused on developing new therapeutic approaches to the treatment of MS.
Nutritional expertise at Northumbria University, Newcastle has helped enhance the menus of a prestigious care provider.
› Verified 8 days ago
| Entity Name | Prima Care Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1265422596 PECOS PAC ID: 2567356017 Enrollment ID: O20040214000027 |
News Archive
A team of scientists, led by researchers at the University of California, San Diego School of Medicine, has shown for the first time how cancer cells control the ON/OFF switch of a program used by developing embryos to effectively metastasize in vivo, breaking free and spreading to other parts of the body, where they can proliferate and grow into secondary tumors.
A new research paper published by scientists at the University of Bristol who sequenced the genome of the SARS-CoV-2 virus, which is causing the worldwide COVID-19 illness, reveals some significant findings that could help researchers working on rolling out vaccines to stop the relentless march of the virus. The study was published online on the preprint site bioRxiv in April 2020.
OncoMed Pharmaceuticals, Inc., a company developing novel therapeutics that target cancer stem cells, announced today that it has been awarded $1.2 million to support five distinct therapeutic programs under the U.S. Government's Qualifying Therapeutic Discovery Project program.
Genzyme, a Sanofi company, announced today the formation of a research collaboration with Cleveland Clinic focused on developing new therapeutic approaches to the treatment of MS.
Nutritional expertise at Northumbria University, Newcastle has helped enhance the menus of a prestigious care provider.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Thomas F Cahill, MD 11 Willow St, Apt. No. 1, Newport, RI 02840-1900 Ph: (508) 679-7709 | Dr Thomas F Cahill, MD 300 Hanover St, Fall River, MA 02720-5444 Ph: (508) 679-7709 |
News Archive
A team of scientists, led by researchers at the University of California, San Diego School of Medicine, has shown for the first time how cancer cells control the ON/OFF switch of a program used by developing embryos to effectively metastasize in vivo, breaking free and spreading to other parts of the body, where they can proliferate and grow into secondary tumors.
A new research paper published by scientists at the University of Bristol who sequenced the genome of the SARS-CoV-2 virus, which is causing the worldwide COVID-19 illness, reveals some significant findings that could help researchers working on rolling out vaccines to stop the relentless march of the virus. The study was published online on the preprint site bioRxiv in April 2020.
OncoMed Pharmaceuticals, Inc., a company developing novel therapeutics that target cancer stem cells, announced today that it has been awarded $1.2 million to support five distinct therapeutic programs under the U.S. Government's Qualifying Therapeutic Discovery Project program.
Genzyme, a Sanofi company, announced today the formation of a research collaboration with Cleveland Clinic focused on developing new therapeutic approaches to the treatment of MS.
Nutritional expertise at Northumbria University, Newcastle has helped enhance the menus of a prestigious care provider.
› Verified 8 days ago
Dr. Andrew James Lerrick, M.D. Otolaryngology Medicare: Accepting Medicare Assignments Practice Location: 191 Bedford St, Fall River, MA 02720 Phone: 508-679-7709 Fax: 607-763-7375 | |
Dr. William Edward Oconnor Jr., MD Otolaryngology Medicare: Not Enrolled in Medicare Practice Location: 1030 President Ave, Rm 218, Fall River, MA 02720 Phone: 508-678-4244 Fax: 508-235-6665 |